Compare OVID & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OVID | KMDA |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.5M | 460.3M |
| IPO Year | 2017 | 2013 |
| Metric | OVID | KMDA |
|---|---|---|
| Price | $2.19 | $7.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | $6.02 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 1.6M | 105.2K |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 5.36% |
| EPS Growth | ★ 3.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,252,000.00 | N/A |
| Revenue This Year | N/A | $9.50 |
| Revenue Next Year | N/A | $12.63 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | ★ 1181.27 | N/A |
| 52 Week Low | $1.18 | $6.55 |
| 52 Week High | $3.11 | $9.35 |
| Indicator | OVID | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 34.35 | 37.90 |
| Support Level | $2.18 | $6.94 |
| Resistance Level | $2.79 | $7.71 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 11.69 | 4.72 |
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.